Gemcitabine (Gemzar) / CA19-9 Cancer Research Results

GEM, Gemcitabine (Gemzar): Click to Expand ⟱
Features: Chemo
GEM An IV antimetabolic antineoplastic used with cisplatin for inoperable non-small cell lung CA
Treats cancer of pancreas, lung, ovary and breast.

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Inhibition of DNA synthesis (antimetabolite effect) Incorporated into DNA → chain termination Normal dividing cells affected (bone marrow, GI epithelium) P, R, G Direct cytotoxicity Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is phosphorylated to the triphosphate form (dFdCTP) which competes with dCTP, gets incorporated into DNA, and blocks DNA chain elongation.
2 Ribonucleotide reductase (RNR) inhibition dFdCDP inhibits RNR → deoxynucleotide pool depletion ↔ (normal proliferating cells also impacted) R, G Nucleotide pool imbalance Gemcitabine diphosphate (dFdCDP) inhibits RNR, reducing available dNTPs and enhancing the chain-termination effect.
3 Apoptosis induction (DNA damage response) DNA damage signaling → caspase activation Toxicity in dividing normal tissues G Execution of cell death Prolonged DNA synthesis arrest and replication stress triggers apoptosis pathways via ATR/Chk1, p53, and caspase cascades.
4 Cell-cycle arrest (S-phase accumulation) S-phase arrest steers cells into apoptosis ↔ G Cytostasis → death Accumulation of stalled replication forks enforces S-phase arrest and amplifies cytotoxicity.
5 DNA damage response signaling (ATR/Chk1/Chk2) Checkpoint activation ↔ R, G Damage signaling Replication stress activates ATR/Chk1/Chk2 and modulates cell-cycle checkpoints and repair responses.
6 NF-κB pro-survival signaling (resistance axis) NF-κB activation can reduce sensitivity ↔ R, G Resistance/modulation In some tumor models, NF-κB and other pro-survival axes mediate resistance to gemcitabine cytotoxicity; inhibition sensitizes cells.
7 Autophagy modulation (response to stress) Autophagy ↑ in some contexts (cytoprotective) ↔ G Adaptive stress response Gemcitabine can induce autophagy as a survival mechanism in some models; autophagy inhibition can sensitize cells in combination studies.
8 Reactive oxygen species (ROS) elevation (indirect) ROS ↑ (reported in some models) ↔ G Stress amplification Some preclinical studies report ROS increases secondary to replication stress; not a primary mechanism but modulates cell-death pathways.
9 Clinical resistance mechanisms (CDA, nucleoside transporters) CDA ↑; hENT1 ↓ correlates with resistance — G Resistance / exposure constraint Cytidine deaminase (CDA) inactivates gemcitabine; lower hENT1 transport reduces uptake — major clinical resistance factors.
10 Bioavailability / pharmacokinetics (IV dosing; systemic exposure) IV infusion achieves systemic levels ↔ — PK constraint Gemcitabine is given systemically (often IV) and achieves cytotoxic blood levels; rapid deamination by CDA and short half-life shape dosing.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid biochemical activation / early metabolic engagement)
  • R: 30 min–3 hr (acute nucleotide pool effects / checkpoint signaling)
  • G: >3 hr (DNA damage response, cell death, phenotype outcomes)
CA19-9, CA 19-9: Click to Expand ⟱
Source:
Type: biomarker
CA 19-9 and Cancer — Tumor Burden Marker, Treatment Monitoring Tool, and Its Limits
CA 19-9 (also known as sialyl-Lewis A) is a glycan epitope expressed on mucins and other glycoproteins. It is not a gene and not a cancer-specific molecule by design.

Typically UPREGULATED in circulation in certain cancers due to increased production and/or impaired biliary clearance.
Elevation reflects tumor burden and ductal involvement, not oncogenic signaling.
Where CA 19-9 Is Clinically Relevant
Highest utility:
-Pancreatic ductal adenocarcinoma (PDAC)
-Cholangiocarcinoma
-Gallbladder cancer

Secondary/limited utility:
-Gastric and colorectal cancers (subset; nonspecific)

Appropriate uses
-Baseline assessment at diagnosis (prognostic)
-Monitoring response to therapy
-Detecting recurrence after treatment
-Trend analysis over time (most important)

CA 19-9 can be elevated without cancer, especially with:
-Biliary obstruction or cholestasis
-Cholangitis or pancreatitis
-Liver disease

The Lewis Antigen Issue (Often Missed)
~5–10% of people are Lewis antigen–negative (Leᵃ⁻ᵇ⁻) and cannot synthesize CA 19-9.
Implications:
-CA 19-9 may be falsely low or undetectable despite advanced cancer
-A “normal” CA 19-9 does not exclude disease in these patients

Higher baseline CA 19-9 → worse prognosis (on average)


Scientific Papers found: Click to Expand⟱
7505- HCQ,  GEM,  PacT,    A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
- Trial, PC, NA
eff↑, TumAuto↓, Imm↑, CA19-9↓, OS↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Imm↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CA19-9↓, 1,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: CA19-9, CA 19-9
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:84  Target#:1412  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page